Reverse-Payment Settlements: Demystifying the Current State of Pharmaceutical Litigation Settlements in the Hatch-Waxman Context

April 20, 2023 1:45pm

Julia Chapman
Dechert LLP

Benjamin M. Greenblum
Williams & Connolly LLP

Kurt Mathas
Winston & Strawn LLP

Robert Milne
White & Case LLP

Alyson Wooten
Managing Director
Berkeley Research Group LLC

  • Understanding settlement strategies between brands and generics
  • Structuring agreements and identifying antitrust concerns
    • Understanding investigation and liability risks
  • Highlighting the state legislation directly addressing “reverse payment” patent settlements
    • Presumption of unlawfulness – California AB 824
  • Reviewing the proper standards of antitrust review and the rising call for a legislative response
    • Analyzing the current legislative and regulatory framework
    • Mergers, acquisitions, and exclusive licenses
    • Anticompetitive agreements
    • Abuse of dominance
    • Life cycle management and contracting
    • Pricing strategies
  • Avoiding costly litigation and associated penalties by effectively complying with the law
  • At-Risk Launch considerations